Advertisement
UK markets close in 4 hours 51 minutes
  • FTSE 100

    8,088.55
    +48.17 (+0.60%)
     
  • FTSE 250

    19,705.29
    -14.08 (-0.07%)
     
  • AIM

    755.23
    +0.54 (+0.07%)
     
  • GBP/EUR

    1.1668
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2514
    +0.0051 (+0.41%)
     
  • Bitcoin GBP

    50,714.30
    -2,349.65 (-4.43%)
     
  • CMC Crypto 200

    1,351.81
    -30.76 (-2.22%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.83
    +0.02 (+0.02%)
     
  • GOLD FUTURES

    2,338.90
    +0.50 (+0.02%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,968.26
    -120.44 (-0.67%)
     
  • CAC 40

    8,027.89
    -63.97 (-0.79%)
     

Global Anticoagulants Market to Reach $74.3 Billion by 2030

ReportLinker
ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, March 09, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Anticoagulants Industry" - https://www.reportlinker.com/p098261/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Anticoagulants Market to Reach $74.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Anticoagulants estimated at US$38.1 Billion in the year 2022, is projected to reach a revised size of US$74.3 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. NOACs, one of the segments analyzed in the report, is projected to record 10.9% CAGR and reach US$33.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Xarelto segment is readjusted to a revised 6.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $10.4 Billion, While China is Forecast to Grow at 15.4% CAGR

The Anticoagulants market in the U.S. is estimated at US$10.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$20.1 Billion by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 7.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Select Competitors (Total 48 Featured)
- Abbott India Limited
- Aspen Holdings
- Bayer Healthcare AG
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Mitsubishi Tanabe Pharma Corp.
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.


Read the full report: https://www.reportlinker.com/p098261/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Venous ThromboEmbolism (VTE) - A Prelude
Recent Market Activity
Anticoagulants Market Driven by Novel Oral Anti-coagulants
Sizing the Market
Safety Issues Associated with Erstwhile Market Leaders -
Warfarin & Heparins
Anticoagulants - Evolution from Injectables to Oral Drugs
Conventional Oral Drug - Warfarin - Face the Heat
The Newer Breed of NOACs
Comparative Analysis of Warfarin and Novel Oral Anticoagulants
Bevyxxa (Betrixaban) - The Latest Approved NOAC
Aging Population: A Crucial Driver for Anticoagulants Market
Global Menace of Cardiovascular Disease - A Major Growth Factor
Increasing Prevalence of AF Impacts Growth Prospects
Rising Stroke Statistics - An Opportunity Indicator for
Anticoagulants
Increasing Incidence of Knee/Hip Replacement Surgeries Drive
Market Growth
Increasing Healthcare Spending in Emerging Markets
Adverse Effects: A Key Market Deterrent
Common Adverse Effects of NOAC Therapies
Increased Bleeding - A Major Concern with Newer Agents
Novel Oral Drugs: Absence of Antidote & Other Concerns
US FDA Delays Andexxa (the Xarelto and Eliquis Antidote) Approval
Reversal Agents for DOACs
Threat of Generics Looms Large on the Anti-Coagulants Market
Patent Expiries of Oral Anticoagulants
Pipeline Analysis
Tecarfarin (Espero BioPharma)
List of Ongoing NOAC Studies
Anticoagulants - Global Key Competitors Percentage Market Share
in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS
Abbott India Limited (India)
Aspen Holdings (South Africa)
Bayer AG (Germany)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb Company (USA)
Mitsubishi Tanabe Pharma Corporation (Japan)
Pfizer, Inc. (USA)
Sanofi S.A. (France)
Teva Pharmaceutical Industries Ltd. (Israel)

3. MARKET TRENDS & DRIVERS
NOACs to Emerge as Mainstream Option for VTE Patients
NICE Guidelines Promote NOAC Usage in Atrial Fibrillation
NOACs as Alternative/Supplement to Antiplatelet Therapy
Increase in Heparin Trade Boosts the Market
Modern Developments Improving Anticoagulation Management
Researchers Find Significant Correlation between NAOC and Newer
Health Risks
NOAC Underdosing Trend Restrains Universal Acceptance
Underutilization of Oral Anticoagulants in Atrial Fibrillation
Generics Prevail in the Traditional Market
Patent Expiries of Traditional Anticoagulants in the US
Inadequate Trials Mar Pediatric Anticoagulants Market
New Advancements Improve Anticoagulation Management
Growing Demand for Self-Testing
LMWHs Ease Outpatient Management

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Anticoagulants by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Anticoagulants by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 3: World 16-Year Perspective for Anticoagulants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for NOACs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 5: World Historic Review for NOACs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for NOACs by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Xarelto by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Xarelto by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 9: World 16-Year Perspective for Xarelto by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Heparin & LMWH by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Heparin & LMWH by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for Heparin & LMWH by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Vitamin K Antagonist by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Vitamin K Antagonist by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Vitamin K Antagonist by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Other Drug Classes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Other Drug Classes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Other Drug Classes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for Oral
Anticoagulant by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Oral Anticoagulant by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Oral Anticoagulant by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Injectable Anticoagulant by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Injectable Anticoagulant by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Injectable
Anticoagulant by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Atrial Fibrillation by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Atrial Fibrillation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Atrial Fibrillation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Stroke by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Stroke by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 30: World 16-Year Perspective for Stroke by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 31: World Recent Past, Current & Future Analysis for
Pulmonary Embolism (PE) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 32: World Historic Review for Pulmonary Embolism (PE) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 33: World 16-Year Perspective for Pulmonary Embolism (PE)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 34: World Recent Past, Current & Future Analysis for Deep
Vein Thrombosis (DVT) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 35: World Historic Review for Deep Vein Thrombosis (DVT)
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 36: World 16-Year Perspective for Deep Vein Thrombosis
(DVT) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 37: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 38: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 39: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 40: World Anticoagulants Market Analysis of Annual Sales
in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Anticoagulants Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 41: USA Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 42: USA Historic Review for Anticoagulants by Drug Class -
NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and
Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 43: USA 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 44: USA Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 45: USA Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 46: USA 16-Year Perspective for Anticoagulants by Route
Of Administration - Percentage Breakdown of Value Sales for
Oral Anticoagulant and Injectable Anticoagulant for the Years
2014, 2023 & 2030

Table 47: USA Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 48: USA Historic Review for Anticoagulants by Application -
Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep
Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 49: USA 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

CANADA
Table 50: Canada Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 51: Canada Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 52: Canada 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 53: Canada Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 54: Canada Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 55: Canada 16-Year Perspective for Anticoagulants by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral Anticoagulant and Injectable Anticoagulant for the
Years 2014, 2023 & 2030

Table 56: Canada Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 57: Canada Historic Review for Anticoagulants by
Application - Atrial Fibrillation, Stroke, Pulmonary Embolism
(PE), Deep Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 58: Canada 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

JAPAN
Anticoagulants Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 59: Japan Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 60: Japan Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 61: Japan 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 62: Japan Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 63: Japan Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Japan 16-Year Perspective for Anticoagulants by Route
Of Administration - Percentage Breakdown of Value Sales for
Oral Anticoagulant and Injectable Anticoagulant for the Years
2014, 2023 & 2030

Table 65: Japan Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 66: Japan Historic Review for Anticoagulants by
Application - Atrial Fibrillation, Stroke, Pulmonary Embolism
(PE), Deep Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 67: Japan 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

CHINA
Anticoagulants Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 68: China Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 69: China Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 70: China 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 71: China Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 72: China Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 73: China 16-Year Perspective for Anticoagulants by Route
Of Administration - Percentage Breakdown of Value Sales for
Oral Anticoagulant and Injectable Anticoagulant for the Years
2014, 2023 & 2030

Table 74: China Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 75: China Historic Review for Anticoagulants by
Application - Atrial Fibrillation, Stroke, Pulmonary Embolism
(PE), Deep Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 76: China 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

EUROPE
Anticoagulants Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 77: Europe Recent Past, Current & Future Analysis for
Anticoagulants by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 78: Europe Historic Review for Anticoagulants by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 79: Europe 16-Year Perspective for Anticoagulants by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 80: Europe Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 81: Europe Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 82: Europe 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 83: Europe Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 84: Europe Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 85: Europe 16-Year Perspective for Anticoagulants by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral Anticoagulant and Injectable Anticoagulant for the
Years 2014, 2023 & 2030

Table 86: Europe Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 87: Europe Historic Review for Anticoagulants by
Application - Atrial Fibrillation, Stroke, Pulmonary Embolism
(PE), Deep Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 88: Europe 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

FRANCE
Anticoagulants Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 89: France Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 90: France Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 91: France 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 92: France Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 93: France Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 94: France 16-Year Perspective for Anticoagulants by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral Anticoagulant and Injectable Anticoagulant for the
Years 2014, 2023 & 2030

Table 95: France Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 96: France Historic Review for Anticoagulants by
Application - Atrial Fibrillation, Stroke, Pulmonary Embolism
(PE), Deep Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 97: France 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

GERMANY
Anticoagulants Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2023 (E)
Table 98: Germany Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 99: Germany Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 100: Germany 16-Year Perspective for Anticoagulants by
Drug Class - Percentage Breakdown of Value Sales for NOACs,
Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug
Classes for the Years 2014, 2023 & 2030

Table 101: Germany Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 102: Germany Historic Review for Anticoagulants by Route
Of Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 103: Germany 16-Year Perspective for Anticoagulants by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral Anticoagulant and Injectable Anticoagulant for the
Years 2014, 2023 & 2030

Table 104: Germany Recent Past, Current & Future Analysis for
Anticoagulants by Application - Atrial Fibrillation, Stroke,
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 105: Germany Historic Review for Anticoagulants by
Application - Atrial Fibrillation, Stroke, Pulmonary Embolism
(PE), Deep Vein Thrombosis (DVT) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 106: Germany 16-Year Perspective for Anticoagulants by
Application - Percentage Breakdown of Value Sales for Atrial
Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT) and Other Applications for the Years 2014,
2023 & 2030

ITALY
Table 107: Italy Recent Past, Current & Future Analysis for
Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH,
Vitamin K Antagonist and Other Drug Classes - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 108: Italy Historic Review for Anticoagulants by Drug
Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist
and Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 109: Italy 16-Year Perspective for Anticoagulants by Drug
Class - Percentage Breakdown of Value Sales for NOACs, Xarelto,
Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for
the Years 2014, 2023 & 2030

Table 110: Italy Recent Past, Current & Future Analysis for
Anticoagulants by Route Of Administration - Oral Anticoagulant
and Injectable Anticoagulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 111: Italy Historic Review for Anticoagulants by Route Of
Administration - Oral Anticoagulant and Injectable
Anticoagulant Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 112: Italy 16-Year Perspective for Anticoagulants by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral Anticoagulant and Injectable Anticoagulant for the
Years 2014, 2023 & 2030

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p098261/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001